Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis

Alessia Fornoni, Junichiro Sageshima, Changli Wei, Sandra Merscher-Gomez, Robier Aguillon-Prada, Alexandra N. Jauregui, Jing Li, Adela Mattiazzi, Gaetano Ciancio, Linda Chen, Gaston Zilleruelo, Carolyn Abitbol, Jayanthi Chandar, Wacheree Seeherunvong, Camillo Ricordi, Masami Ikehata, Maria Pia Rastaldi, Jochen Reiser, George W. Burke

Research output: Contribution to journalArticle

268 Citations (Scopus)

Abstract

Focal segmental glomerulosclerosis (FSGS) is a glomerular disease characterized by proteinuria, progression to endstage renal disease, and recurrence of proteinuria after kidney transplantation in about one-third of patients. It has been suggested that rituximab might treat recurrent FSGS through an unknown mechanism. Rituximab not only recognizes CD20 on B lymphocytes, but might also bind sphingomyelin phosphodiesterase acid-like 3b (SMPDL-3b) protein and regulate acid sphingomyelinase (ASMase) activity. We hypothesized that rituximab prevents recurrent FSGS and preserves podocyte SMPDL-3b expression. We studied 41 patients at high risk for recurrent FSGS, 27 of whom were treated with rituximab at time of kidney transplant. SMPDL-3b protein, ASMase activity, and cytoskeleton remodeling were studied in cultured normal human podocytes that had been exposed to patient sera with or without rituximab. Rituximab treatment was associated with lower incidence of posttransplant proteinuria and stabilization of glomerular filtration rate. The number of SMPDL-3b+ podocytes in postreperfusion biopsies was reduced in patients who developed recurrent FSGS. Rituximab partially prevented SMPDL-3b and ASMase down-regulation that was observed in podocytes treated with the sera of patients with recurrent FSGS. Overexpression of SMPDL-3b or treatment with rituximab was able to prevent disruption of the actin cytoskeleton and podocyte apoptosis induced by patient sera. This effect was diminished in cultured podocytes where SMPDL-3b was silenced. Our study suggests that treatment of high-risk patients with rituximab at time of kidney transplant might prevent recurrent FSGS by modulating podocyte function in an SMPDL-3b-dependent manner.

Original languageEnglish
Article number85ra46
JournalScience Translational Medicine
Volume3
Issue number85
DOIs
Publication statusPublished - Jun 1 2011

Fingerprint

Sphingomyelin Phosphodiesterase
Focal Segmental Glomerulosclerosis
Podocytes
Acids
Proteinuria
Kidney
Rituximab
Serum
Transplants
Cytoskeleton
Glomerular Filtration Rate
Actin Cytoskeleton
Kidney Transplantation
Proteins
B-Lymphocytes
Therapeutics
Down-Regulation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fornoni, A., Sageshima, J., Wei, C., Merscher-Gomez, S., Aguillon-Prada, R., Jauregui, A. N., ... Burke, G. W. (2011). Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Science Translational Medicine, 3(85), [85ra46]. https://doi.org/10.1126/scitranslmed.3002231

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. / Fornoni, Alessia; Sageshima, Junichiro; Wei, Changli; Merscher-Gomez, Sandra; Aguillon-Prada, Robier; Jauregui, Alexandra N.; Li, Jing; Mattiazzi, Adela; Ciancio, Gaetano; Chen, Linda; Zilleruelo, Gaston; Abitbol, Carolyn; Chandar, Jayanthi; Seeherunvong, Wacheree; Ricordi, Camillo; Ikehata, Masami; Rastaldi, Maria Pia; Reiser, Jochen; Burke, George W.

In: Science Translational Medicine, Vol. 3, No. 85, 85ra46, 01.06.2011.

Research output: Contribution to journalArticle

Fornoni, A, Sageshima, J, Wei, C, Merscher-Gomez, S, Aguillon-Prada, R, Jauregui, AN, Li, J, Mattiazzi, A, Ciancio, G, Chen, L, Zilleruelo, G, Abitbol, C, Chandar, J, Seeherunvong, W, Ricordi, C, Ikehata, M, Rastaldi, MP, Reiser, J & Burke, GW 2011, 'Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis', Science Translational Medicine, vol. 3, no. 85, 85ra46. https://doi.org/10.1126/scitranslmed.3002231
Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Science Translational Medicine. 2011 Jun 1;3(85). 85ra46. https://doi.org/10.1126/scitranslmed.3002231
Fornoni, Alessia ; Sageshima, Junichiro ; Wei, Changli ; Merscher-Gomez, Sandra ; Aguillon-Prada, Robier ; Jauregui, Alexandra N. ; Li, Jing ; Mattiazzi, Adela ; Ciancio, Gaetano ; Chen, Linda ; Zilleruelo, Gaston ; Abitbol, Carolyn ; Chandar, Jayanthi ; Seeherunvong, Wacheree ; Ricordi, Camillo ; Ikehata, Masami ; Rastaldi, Maria Pia ; Reiser, Jochen ; Burke, George W. / Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. In: Science Translational Medicine. 2011 ; Vol. 3, No. 85.
@article{7b03d2eb0cf1429d910ac016d8d37f13,
title = "Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis",
abstract = "Focal segmental glomerulosclerosis (FSGS) is a glomerular disease characterized by proteinuria, progression to endstage renal disease, and recurrence of proteinuria after kidney transplantation in about one-third of patients. It has been suggested that rituximab might treat recurrent FSGS through an unknown mechanism. Rituximab not only recognizes CD20 on B lymphocytes, but might also bind sphingomyelin phosphodiesterase acid-like 3b (SMPDL-3b) protein and regulate acid sphingomyelinase (ASMase) activity. We hypothesized that rituximab prevents recurrent FSGS and preserves podocyte SMPDL-3b expression. We studied 41 patients at high risk for recurrent FSGS, 27 of whom were treated with rituximab at time of kidney transplant. SMPDL-3b protein, ASMase activity, and cytoskeleton remodeling were studied in cultured normal human podocytes that had been exposed to patient sera with or without rituximab. Rituximab treatment was associated with lower incidence of posttransplant proteinuria and stabilization of glomerular filtration rate. The number of SMPDL-3b+ podocytes in postreperfusion biopsies was reduced in patients who developed recurrent FSGS. Rituximab partially prevented SMPDL-3b and ASMase down-regulation that was observed in podocytes treated with the sera of patients with recurrent FSGS. Overexpression of SMPDL-3b or treatment with rituximab was able to prevent disruption of the actin cytoskeleton and podocyte apoptosis induced by patient sera. This effect was diminished in cultured podocytes where SMPDL-3b was silenced. Our study suggests that treatment of high-risk patients with rituximab at time of kidney transplant might prevent recurrent FSGS by modulating podocyte function in an SMPDL-3b-dependent manner.",
author = "Alessia Fornoni and Junichiro Sageshima and Changli Wei and Sandra Merscher-Gomez and Robier Aguillon-Prada and Jauregui, {Alexandra N.} and Jing Li and Adela Mattiazzi and Gaetano Ciancio and Linda Chen and Gaston Zilleruelo and Carolyn Abitbol and Jayanthi Chandar and Wacheree Seeherunvong and Camillo Ricordi and Masami Ikehata and Rastaldi, {Maria Pia} and Jochen Reiser and Burke, {George W.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1126/scitranslmed.3002231",
language = "English",
volume = "3",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "85",

}

TY - JOUR

T1 - Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis

AU - Fornoni, Alessia

AU - Sageshima, Junichiro

AU - Wei, Changli

AU - Merscher-Gomez, Sandra

AU - Aguillon-Prada, Robier

AU - Jauregui, Alexandra N.

AU - Li, Jing

AU - Mattiazzi, Adela

AU - Ciancio, Gaetano

AU - Chen, Linda

AU - Zilleruelo, Gaston

AU - Abitbol, Carolyn

AU - Chandar, Jayanthi

AU - Seeherunvong, Wacheree

AU - Ricordi, Camillo

AU - Ikehata, Masami

AU - Rastaldi, Maria Pia

AU - Reiser, Jochen

AU - Burke, George W.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Focal segmental glomerulosclerosis (FSGS) is a glomerular disease characterized by proteinuria, progression to endstage renal disease, and recurrence of proteinuria after kidney transplantation in about one-third of patients. It has been suggested that rituximab might treat recurrent FSGS through an unknown mechanism. Rituximab not only recognizes CD20 on B lymphocytes, but might also bind sphingomyelin phosphodiesterase acid-like 3b (SMPDL-3b) protein and regulate acid sphingomyelinase (ASMase) activity. We hypothesized that rituximab prevents recurrent FSGS and preserves podocyte SMPDL-3b expression. We studied 41 patients at high risk for recurrent FSGS, 27 of whom were treated with rituximab at time of kidney transplant. SMPDL-3b protein, ASMase activity, and cytoskeleton remodeling were studied in cultured normal human podocytes that had been exposed to patient sera with or without rituximab. Rituximab treatment was associated with lower incidence of posttransplant proteinuria and stabilization of glomerular filtration rate. The number of SMPDL-3b+ podocytes in postreperfusion biopsies was reduced in patients who developed recurrent FSGS. Rituximab partially prevented SMPDL-3b and ASMase down-regulation that was observed in podocytes treated with the sera of patients with recurrent FSGS. Overexpression of SMPDL-3b or treatment with rituximab was able to prevent disruption of the actin cytoskeleton and podocyte apoptosis induced by patient sera. This effect was diminished in cultured podocytes where SMPDL-3b was silenced. Our study suggests that treatment of high-risk patients with rituximab at time of kidney transplant might prevent recurrent FSGS by modulating podocyte function in an SMPDL-3b-dependent manner.

AB - Focal segmental glomerulosclerosis (FSGS) is a glomerular disease characterized by proteinuria, progression to endstage renal disease, and recurrence of proteinuria after kidney transplantation in about one-third of patients. It has been suggested that rituximab might treat recurrent FSGS through an unknown mechanism. Rituximab not only recognizes CD20 on B lymphocytes, but might also bind sphingomyelin phosphodiesterase acid-like 3b (SMPDL-3b) protein and regulate acid sphingomyelinase (ASMase) activity. We hypothesized that rituximab prevents recurrent FSGS and preserves podocyte SMPDL-3b expression. We studied 41 patients at high risk for recurrent FSGS, 27 of whom were treated with rituximab at time of kidney transplant. SMPDL-3b protein, ASMase activity, and cytoskeleton remodeling were studied in cultured normal human podocytes that had been exposed to patient sera with or without rituximab. Rituximab treatment was associated with lower incidence of posttransplant proteinuria and stabilization of glomerular filtration rate. The number of SMPDL-3b+ podocytes in postreperfusion biopsies was reduced in patients who developed recurrent FSGS. Rituximab partially prevented SMPDL-3b and ASMase down-regulation that was observed in podocytes treated with the sera of patients with recurrent FSGS. Overexpression of SMPDL-3b or treatment with rituximab was able to prevent disruption of the actin cytoskeleton and podocyte apoptosis induced by patient sera. This effect was diminished in cultured podocytes where SMPDL-3b was silenced. Our study suggests that treatment of high-risk patients with rituximab at time of kidney transplant might prevent recurrent FSGS by modulating podocyte function in an SMPDL-3b-dependent manner.

UR - http://www.scopus.com/inward/record.url?scp=79957836560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957836560&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3002231

DO - 10.1126/scitranslmed.3002231

M3 - Article

VL - 3

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 85

M1 - 85ra46

ER -